REFERENCES

1. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011;301:H2181-90.

2. Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol 2013;1:483-91.

3. Resch U, Helsel G, Tatzber F, Sinzinger H. Antioxidant status in thyroid dysfunction. Clin Chem Lab Med 2002;40:1132-4.

4. Mancini A, Di Segni C, Raimondo S, et al. Thyroid Hormones, Oxidative Stress, and Inflammation. Mediators Inflamm 2016;2016:6757154.

5. Gaggini M, Traghella I, Vassalle C. The Thyroid-Oxidative Stress Axis in Heart Failure. In: Iervasi G, Pingitore A, Gerdes A, Razvi S, editors. Thyroid and Heart. Cham: Springer International Publishing; 2020. pp. 171-86.

6. Mishra P, Samanta L. Oxidative stress and heart failure in altered thyroid States. ScientificWorldJournal 2012;2012:741861.

7. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-478.

8. Lockwood TD. Redox control of protein degradation. Antioxid Redox Signal 2000;2:851-78.

9. Thollon C, Iliou JP, Cambarrat C, Robin F, Vilaine JP. Nature of the cardiomyocyte injury induced by lipid hydroperoxides. Cardiovasc Res 1995;30:648-55.

10. Schulz E, Wenzel P, Münzel T, Daiber A. Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal 2014;20:308-24.

11. Daiber A, Di Lisa F, Oelze M, et al. Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function. Br J Pharmacol 2017;174:1670-89.

12. Hernanz R, Briones AM, Salaices M, Alonso MJ. New roles for old pathways? A circuitous relationship between reactive oxygen species and cyclo-oxygenase in hypertension. Clin Sci (Lond) 2014;126:111-21.

13. Dubois-Deruy E, Peugnet V, Turkieh A, Pinet F. Oxidative Stress in Cardiovascular Diseases. Antioxidants (Basel) 2020;9:864.

14. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol 2018;217:1915-28.

15. Mastorci F, Sabatino L, Vassalle C, Pingitore A. Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure. Front Endocrinol (Lausanne) 2019;10:927.

16. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-9.

17. Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol 2010;59:1-30.

18. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996;79:1059-63.

19. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005;26:704-28.

20. Morkin E, Flink I, Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Progress in Cardiovascular Diseases 1983;25:435-64.

21. Mai W, Janier MF, Allioli N, et al. Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci U S A 2004;101:10332-7.

22. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol 2016;12:111-21.

23. Wickenden AD, Kaprielian R, Parker TG, Jones OT, Backx PH. Effects of development and thyroid hormone on K+ currents and K+ channel gene expression in rat ventricle. J Physiol 1997;504:271-86.

24. Cernohorský J, Kolár F, Pelouch V, Korecky B, Vetter R. Thyroid control of sarcolemmal Na+/Ca2+ exchanger and SR Ca2+-ATPase in developing rat heart. Am J Physiol 1998;275:H264-73.

25. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-9.

26. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170:191-203.

27. Herbert J, Bono F, Savi P. The mitogenic effect of H ₂ O ₂ for vascular smooth muscle cells is mediated by an increase of the affinity of basic fibroblast growth factor for its receptor. FEBS Letters 1996;395:43-7.

28. Delafontaine P, Ku L. Reactive oxygen species stimulate insulin-like growth factor I synthesis in vascular smooth muscle cells. Cardiovasc Res 1997;33:216-22.

29. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012;366:54-63.

30. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012;110:159-73.

31. Mukherjee SB, Das M, Sudhandiran G, Shaha C. Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J Biol Chem 2002;277:24717-27.

32. Sheeran FL, Pepe S. Mitochondrial Bioenergetics and Dysfunction in Failing Heart. Adv Exp Med Biol 2017;982:65-80.

33. Sheeran FL, Pepe S. Energy deficiency in the failing heart: linking increased reactive oxygen species and disruption of oxidative phosphorylation rate. Biochim Biophys Acta 2006;1757:543-52.

34. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 1995;46:455-66.

35. Cappola TP. Molecular remodeling in human heart failure. J Am Coll Cardiol 2008;51:137-8.

36. Sabatino L. TH Treatment in Patients with Cardiac Disorders: General Aspects and Rationale. In: Iervasi G, Pingitore A, Gerdes A, Razvi S, editors. Thyroid and Heart. Cham: Springer International Publishing; 2020. pp. 373-80.

37. Swynghedauw B, Delcayre C, Samuel JL, Mebazaa A, Cohen-Solal A. Molecular mechanisms in evolutionary cardiology failure. Ann N Y Acad Sci 2010;1188:58-67.

38. Klein I, Ojamaa K. Thyroid hormone-targeting the heart. Endocrinology 2001;142:11-2.

39. Wang B, Liu S, Li L, et al. Non-thyroidal illness syndrome in patients with cardiovascular diseases: A systematic review and meta-analysis. Int J Cardiol 2017;226:1-10.

40. Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005;118:132-6.

41. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23:38-89.

42. Ortiz VD, de Castro AL, Campos C, et al. Effects of thyroid hormones on aortic tissue after myocardial infarction in rats. Eur J Pharmacol 2016;791:788-93.

43. Yao J, Eghbali M. Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy. Response of cardiac fibroblasts to thyroid hormone in vitro. Circ Res 1992;71:831-9.

44. Kmiec Z, Myśliwska J, Rachón D, Kotlarz G, Sworczak K, Myśliwski A. Natural killer activity and thyroid hormone levels in young and elderly persons. Gerontology 2001;47:282-8.

45. Sabatino L, Balzan S, Kusmic C, Iervasi G. Modification of gene expression profiling related to renin-angiotensin system in an ischemia/reperfusion rat model after T3 infusion. Mol Cell Biochem 2018;449:277-83.

46. Janssen R, Zuidwijk MJ, Kuster DW, Muller A, Simonides WS. Thyroid Hormone-Regulated Cardiac microRNAs are Predicted to Suppress Pathological Hypertrophic Signaling. Front Endocrinol (Lausanne) 2014;5:171.

47. Danzi S, Ojamaa K, Klein I. Triiodothyronine-mediated myosin heavy chain gene transcription in the heart. Am J Physiol Heart Circ Physiol 2003;284:H2255-62.

48. Rybin V, Steinberg SF. Thyroid hormone represses protein kinase C isoform expression and activity in rat cardiac myocytes. Circ Res 1996;79:388-98.

49. Ferreira JC, Brum PC, Mochly-Rosen D. βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 2011;51:479-84.